Upload
jasriena
View
749
Download
3
Tags:
Embed Size (px)
DESCRIPTION
Therapeutic Plasma Exchange
Citation preview
Dr. Michel HelmyProduct Manager ‐ ICMiddle East & East Africa
TPETPE TrainingTrainingKanoo Kidney Center
Dammam – KSA17th -19th November 2008
© 2008 – Dr. Michel Helmy / IC Product Manager 2
AgendaAgenda – Day 33
• TPE on PrismaFlex
• Practice (HANDS 0N)
• Demonstration on actual patient
© 2008 – Dr. Michel Helmy / IC Product Manager 3
TPETPEwithwith PrismaFlexPrismaFlex®
© 2008 – Dr. Michel Helmy / IC Product Manager 4
What is Aphaeresis?
© 2008 – Dr. Michel Helmy / IC Product Manager 5
“A separation of whole blood into its cellular components. A selected component is removed and the remaining elements are recombined and returned to the donor”.
American Society of Aphaeresis;
Principles of Apheresis Technology
Aphaeresis
© 2008 – Dr. Michel Helmy / IC Product Manager 6
“ Cytapheresis”•Selective removal of any cellular component of whole blood, and can be done with Centrifugal machinery.
For example:
Definitions:
“Erythrocytapheresis”:•Removal of Erythrocytes (RBC).•Used to treat life-threatening autoimmune hemolysis, and parasitemia in Malaria.
© 2008 – Dr. Michel Helmy / IC Product Manager 7
“Thrombocytapheresis”:•Removal of platelets for patients with myeloproliferative diseases such as polycythemia vera, primary thrombocytemia and chronic granulocytic leukemia, who are at risk of, or symptomatic of thrombotic or hemorrhagic complications.
Definitions:
© 2008 – Dr. Michel Helmy / IC Product Manager 8
“Plasmapheresis”: “(TPE)”
•The procedures in which the patient’s plasma is separated and removed from the whole blood.
•The removed plasma is replaced 1:1 ratio with a replacement solution i.e. Albumin or FFP.
•To treat autoimmune conditions such as Myasthenia Gravis, TTP and Guillian-Barre’ Syndrome.
Definitions:
© 2008 – Dr. Michel Helmy / IC Product Manager 9
-Packed RBCs being the heaviest blood
component with a specific gravity of 1.75 are separated along the outside wall of the spinning channel. The “Buffy coat”in the center of the channel consists of WBCs, Platelets, and Stem cells. Platelets have a specific gravity of 1.04. Plasma is the lightest blood component with a specific gravity of 1.025.
10
REMOVES:• Immune complexes• Immunoglobulins
(IgG, IgM, IgA)• Cholesterol• Albumin• Fibrinogen• Urea, Creatinin• Electrolytes• Plasma protein bound
often the therapy of choice because itscapabilities of removing very large molecules to treat various disease conditions.
Therapeutic Plasma Exchange
© 2008 – Dr. Michel Helmy / IC Product Manager 11
Good pasture’s syndrome •Inflammatory mediators
Poisons/drug OD •Dilantin, mushrooms
TTP •Replacement of plasma deficiencies
Deficiency of LDL •Familial Hypercholesterolemia
Common Diseases treated with TPE
© 2008 – Dr. Michel Helmy / IC Product Manager 12
Indications of TPE:
•Microagiopathic Thrombocytopenia (TTP / HUS).•Respiratory Failure in Guillian-Barre’ Syndrome or Myasthenia Gravis.•Acute poisoning for certain mushrooms or with other strongly protein bound poisons.•Hyperviscosity syndrome with s&s suggesting impending stroke or loss of vision.•Anti – GMB disease & / or pulmonary hemorrhage in Good Pasture’s Syndrome.
Emergency Indications:
© 2008 – Dr. Michel Helmy / IC Product Manager 13
•Good Pasture’s Syndrome•TTP / HUS•Cryoglobulinemia•Hyperviscosity Syndrome•Familial Hypercholesterolemia•Myasthenic crisis•SLE cerebritis (lupus)•Myeloma cast nephropathy•Coagulation factors inhibitor•Systemic vasculitis
Indications of TPE:Primary Indications:
© 2008 – Dr. Michel Helmy / IC Product Manager 14
Mechanisms of action for TPE:Purpose of TPE Target Mediator to be
removedDisease conditionExample:
Removal of abnormal circulating factors (found in Plasma)
Replenishment of specific plasma factors (Immunoglobulin, clotting factors)
• Antibody•Monoclonal Protein• Circulating Immune complexes• Toxic factor
• None
• Myasthenia Gravis• Myeloma Protein• Cryoglobulinemia• TTP / HUS
• TTP
© 2008 – Dr. Michel Helmy / IC Product Manager 15
TPE Categorization…
Category I: Conditions for which therapeutic hemapheresis is standard and acceptable treatment as primary or important secondary treatment.
Category II: Conditions for which sufficient data has shown hemapheresis effective in conjunction with other modalities.
© 2008 – Dr. Michel Helmy / IC Product Manager 16
TPE Categorization…
Category III: Conditions for which there is insufficient evidence to evaluate efficacy and benefit:risk ratio. TPE might be used if other tx’s have failed or experimentally.
© 2008 – Dr. Michel Helmy / IC Product Manager 17
TPE Categorization…
Category IV: Controlled trials have shown no therapeutic efficacy. TPE is discouraged as a treatment choice.
Category V: Pending further investigation by committee.
© 2008 – Dr. Michel Helmy / IC Product Manager 18
Mechanisms of action for TPE:
Purpose of TPE Target Mediator to be removed
Disease conditionExample:
Other effects on the Immune system
• Removal of Inflammatory Mediators (Cytokines, complement)
• Sepsis
© 2008 – Dr. Michel Helmy / IC Product Manager 19
Principles of Treatment
1. Therapy should almost always include immuno – suppression (i.e. Cortico steroid treatment).
- this will reduce the rate of resynthesis of pathologic antibodies production.
2. Diseases that respond to TPE should be treated early to haltinflammatory response that often contributes to the disease progression.
© 2008 – Dr. Michel Helmy / IC Product Manager 20
a. Immunoglobulins have a long half life;- 21 days for IgG - 5 days for IgM
Principles of Treatment
3. Knowledge of the Kinetics of immunoglobulin removal;
© 2008 – Dr. Michel Helmy / IC Product Manager 21
Principles of Treatment
b. Immunoglobulins have substantial extravascular distribution. The extent of intravascular vs. extravascular distribution will determine how effectively they can be removed in the course of single TPE session.
Example:Extravascular Distribution of IgG = 50%
IgM = 20%Therefore; depletion of IgM occurs more quickly than that of IgG.
3. Knowledge of the Kinetics of immunoglobulin removal;
© 2008 – Dr. Michel Helmy / IC Product Manager 22
Centrifugation
Plasmafiltration
Technological Application to TPE
© 2008 – Dr. Michel Helmy / IC Product Manager 23
Centrifugation Technique
© 2008 – Dr. Michel Helmy / IC Product Manager 24
Technological Application to TPE:
Centrifugation Technique:
© 2008 – Dr. Michel Helmy / IC Product Manager 25
Membrane Filtration
A plasma membrane separator device is similar to a hemodialyzer in appearances.
Both contain hollow fibers, but the membrane properties are significantly different.
•Dialyzer removes elements up to 50,000 Daltons
•Plasma membrane removes plasma and all dissolved
•components up to 3 million Daltons
© 2008 – Dr. Michel Helmy / IC Product Manager 26
Effluent Infusion or Anticoagulant
Plasma filter
PatientReturn ClampSyringe pump
Air detector
BLD
Blood pump
Access pressureFilter pressure
Return pressure
TPE
Plasma Replacement
© 2008 – Dr. Michel Helmy / IC Product Manager 27
Size of molecules cleared by CRRTMolecular weights
Small MoleculesDiffusion is better than convection
Middle MoleculesConvection better than diffusion
Nothing above 50.000 is clearedNothing above 50.000 is cleared
Mode of removal
Large MoleculesConvection or adsorbtion
© 2008 – Dr. Michel Helmy / IC Product Manager 28
CRRT vs. TPE Goals of Therapy:
CRRT TPE (Plasmafiltation)
• Electrolyte, fluid and pH balance • Removal of plasma containing large proteins and immuno globulins.
• Removal of excess fluid and waste by-products (urea, creatinine)
• Maintain euvolemic state by replacing 1:1 plasma removed and replacement solution.
© 2008 – Dr. Michel Helmy / IC Product Manager 29
CRRT vs. TPE Goals of Therapy:
CRRT TPE (Plasmafiltation)
• Hemofilter • Plasmafilter
• Central venous access required • Central venous required
© 2008 – Dr. Michel Helmy / IC Product Manager 30
Anatomy of Plasmafilter
© 2008 – Dr. Michel Helmy / IC Product Manager 31
Filter SpecificationSpecification PF 2000N (TPE) M100 CRRT
• Molecular Wt. Cut-off• Fiber Material• Hollow Fibers• Membrane• Sterilization• Effective Surface Area• Maximum Pore size• Total volume of circuit• Circuitry differences
3 million DaltonsPolypropylene3,000Semi-permeableETO0.35 m20.5 um88 ml• No dialysate line• Replacement line given post-filter• Extra fluid line attached to access line.
30,000 DaltonsAcrylonitrile (AN69)6,000Semi-permeableETO0.90 m2<0.01 um107 ml• Dialysate line in place• Replacement line usually given pre-filter but can be post or both
© 2008 – Dr. Michel Helmy / IC Product Manager 32
Filter Specification
Pre-connected filter membrane used in both CRRT & TPE. The major differences with the TPE filter set is that it has no dialysate line connected & replacement is always given post-filter.
© 2008 – Dr. Michel Helmy / IC Product Manager 33
Principles of Plasmafiltration:
Filtration
Convection
Sieving Coefficient
© 2008 – Dr. Michel Helmy / IC Product Manager 34
Filtration:
Movement of fluid across the semi-permeable membrane driven by pressure gradient.
Plasma Volume Reduction
Principles of Plasmafiltration:
© 2008 – Dr. Michel Helmy / IC Product Manager 35
Convection:Movement of solutes along with water flow.“ Solvent drag or Solute drag”
•Plasma is the solvent•Solutes; electrolytes, amino acids, vitamins, albumin and immunoglobulin are dragged along with the plasma into the drain.•The more plasma being removed, the more solute loss will occur.
Principles of Plasmafiltration:
© 2008 – Dr. Michel Helmy / IC Product Manager 36
•Solute removal mainly depends on the S.C.•Ratio of solute between the ultra filtrate (Effluent) and the plasma.
• S.C. of 1.0; means a complete passage of solutes from the plasma into the effluent bag.
Principles of Plasmafiltration:
Sieving Coefficient
© 2008 – Dr. Michel Helmy / IC Product Manager 37
Principles of Plasmafiltration:
Sieving Coefficient:
Solute PF 2000 N (SC) M100 (SC)
• Albumin• Total Proteins• Potassium• Creatinine, Urea• Bicarbonate
0. 970.92 (>)1.01.01.0
<0.01<0.021.01.01.0
© 2008 – Dr. Michel Helmy / IC Product Manager 38
Important Point:• TPE performed with a CRRT filter would be ineffective.• CRRT performed with dedicated TPE filter would be life endangering due to constant albumin loss without replacement.
Sieving Coefficient:
© 2008 – Dr. Michel Helmy / IC Product Manager 39
Schematic Set up for TPE Circuitry:
© 2008 – Dr. Michel Helmy / IC Product Manager 40
Components of Therapy
•Calculating the Plasma Volume to be removed.•Replacement Solution•Anticoagulation•Vascular Access•Warming Device
© 2008 – Dr. Michel Helmy / IC Product Manager 41
Estimated Plasma Volume (PV) to exchange:
Example:70 kg patient, the PV would be;70 kg x 40 ml/Kg = 2800 ml or 3000 ml.
• Use nomogram and equations using height, weight and hematocrit in the literature;
• Useful Rule of thumb is to consider Plasma Volume (PV) to be approximately: 40 ml/kg of body weight.
© 2008 – Dr. Michel Helmy / IC Product Manager 42
Physician’s Order; 1.0 or 1.5 Plasma Volume to be ExchangedFor a 70 Kg patient;
A 1.0 or 100% PV exchange would be 3000 ml.A 1.5 or 150% PV exchange would be 4500 ml.
Ensure that you follow the physician’s order for PV to be exchanged.
Estimated Plasma Volume (PV) to exchange:
© 2008 – Dr. Michel Helmy / IC Product Manager 43
Replacement Solutions
Two Basic types of Replacement Fluids;
•Colloids•Crystalloids
© 2008 – Dr. Michel Helmy / IC Product Manager 44
Colloids;Albumin 5%
•Most commonly used replacement solution used in TPE.•Maintains the patient’s colloid oncotic pressure.•Best to check coagulation parameters; such as PT/PTT before the therapy.
© 2008 – Dr. Michel Helmy / IC Product Manager 45
Fresh Frozen Plasma
•High cost, low availability and possible risk of Hepatitis and HIV, this limits the use of FFP.
Important note:•14% of FFP’s volume content is Citrate. If citrate anticoagulation is used,infusion rate should be reduced.
•An anti-histamine is often used to prevent Histamine – mediated responses that maybe associated with Plasma administration.
Colloids;
© 2008 – Dr. Michel Helmy / IC Product Manager 46
•Usual treatment of Hypotension during TPE.•Successful combination with Albumin 5%•One third of Plasma Volume will be NSS.•Remaining Plasma Volume will be 5% Albumin.•Patient’s serum albumin level must be monitored and kept at > 3.5 g/dl when using this combination.
Crystalloid;
Normal Saline:
© 2008 – Dr. Michel Helmy / IC Product Manager 47
Vascular Access
• Good working Catheter is best required for TPE.
• Peripheral IV accesses are not used for TPE / CRRT.
• Most common cause of pressure alarms are due to the vascular accesses.
Other blood purification techniques
Hemoperfusion, New trends
© 2008 – Dr. Michel Helmy / IC Product Manager 49
Hemoperfusion
© 2008 – Dr. Michel Helmy / IC Product Manager 50
Anticoagulant
Return ClampSyringe pumpPatient
Air detector
Blood pump
Access pressureCartridge pressure
Return pressure
Cartridge
Hemoperfusion
© 2008 – Dr. Michel Helmy / IC Product Manager 51
Related to sepsis• Removal of mediators• Timing• Feasibility
Therapy options• High volume• High cut-off• Adsorption
New trends
© 2008 – Dr. Michel Helmy / IC Product Manager 52
• Most important health problem
• Interaction between SIRS and infection = SEPSIS
• Human sepsis is characterized by a systemic action of inflammatory cytokines TNF & IL6 which if persistent causes death
• Sepsis = balance between pro- and anti-inflammatory cytokines
• The objective of an extracorporeal treatment is to remove the mediators that are involved in the cascade
WHY Sepsis
© 2008 – Dr. Michel Helmy / IC Product Manager 53
• A protective shield against peak of circulating mediators
• A therapy of SIRS as a causative condition for MODS
• A bridge towards native Renal/Liver function recovery
• A protective therapy against further ischemic insults
• A therapy with positive impact on other organ function
• Non specific removal
• Clinical safety: hypothermia, nutrition, vascular access, indications,…
Further role in Sepsis